HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Follow-Up Questions
HUTCHMED (China) Ltd のCEOは誰ですか？
Dr. Weiguo Su は HUTCHMED (China) Ltd の Chief Executive Officer で、2017 から在籍しています。
HMDCF の株価パフォーマンスは？
HMDCF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
HUTCHMED (China) Ltd の主な事業テーマや業界は？
HUTCHMED (China) Ltd は Pharmaceuticals 業界、セクターは Health Care に属しています。
